Lung Cancer | Oncology Today with Dr Neil Love: Key Presentations on Lung Cancer from the 2021 ASCO Annual Meeting

published 1 month ago by Dr Neil Love

Featuring an interview with Dr Joel Neal, including the following topics: Analyze the biologic basis for the investigation of immune checkpoint inhibitors for nonmetastatic non-small cell lung cancer (NSCLC), and evaluate available and emerging data documenting the efficacy and safety of anti-PD-1/PD-L1 antibody-based approaches to (neo)adjuvant therapy. Review recent therapeutic advances with anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy or other immunotherapies for metastatic NSCLC, and discern how these approaches can be optimally employed in disease management. Appraise updated data on the efficacy of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this strategy can be appropriately and safely integrated into routine clinical practice. Review published research data documenting the safety and efficacy of EGFR tyrosine kinase inhibitors alone or in combination with other systemic approaches for metastatic NSCLC with an EGFR tumor mutation, and discern how this information should be applied outside of a research setting. Assess the efficacy of commercially available ALK inhibitors for patients with metastatic NSCLC with an ALK rearrangement, and apply this understanding to the selection and sequencing of these drugs as first- and later-line therapy. Recognize other oncogenic pathways (ie, RET, MET, HER2, KRAS, ROS1) mediating the pathogenesis of tumors in unique patient subsets, and recall published and emerging data with commercially available and experimental agents exploiting these targets. Design an optimal approach to the clinical care of patients with small cell lung cancer, considering available and emerging clinical trial findings.  Assess the biologic rationale for ongoing clinical trials evaluating novel agents and strategies for NSCLC, and counsel appropriate patients about availability and participation.  CME information and select publications  

more episodes from Research To Practice | Oncology Videos